Highlights from the Co-Creating Impact Summit 2020

The third annual Co-Creating Impact Summit in collaboration with Novartis’ Impact Valuation Advisory Council – chaired by John Elkington – brought together internal and external thought leaders in the area of ESG, sustainability and impact valuation to discuss and debate on the current status, future perspectives and ways Novartis could be best prepared for the future. 

The hugely successful event with over 1’100 registrations reflected on the most pressing topics around Investors and Sustainability, Climate and Health, the Future of Integrated Reporting, the Role of Governments, and …

/by

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment

  • Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse events
  • Real-world data indicate older children (aged ≥6 months) achieved clinically meaningful benefit with Zolgensma alone, after or in combination with another SMA therapy, with events consistent with the previously described safety profile
  • Zolgensma led to achievement of new milestones years after …
/by

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

  • Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments1

  • Canakinumab development program continues; two Phase III non-small cell lung cancer clinical trials are ongoing in first-line and adjuvant settings2,3 
  • The CANOPY clinical trial program is designed to help answer critical questions about the role …
/by

EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare

The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.

The positive impact of these digital tools has been that they help patients …

/by

EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare

The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient Innovation Summit (EPIS) explored the positive and negative aspects of digital engagement during the COVID-19 pandemic at EPIS 2020 and made recommendations on how patients can continue to benefit from digital engagement in future.

The positive impact of these digital tools has been that they help patients …

/by

Inspiring a daughter to make her own path

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Teaching a daughter the power of purpose

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Challenging a young scientist to focus on patients

At Novartis, we believe in gender equity. We continue to choose to challenge inequity, including through our public pledge with the Equal Pay International Coalition (EPIC) to achieve gender balance in management and further improve our pay equity and transparency processes by 2023.

This International Women’s Day, we want to celebrate our progress while continuing to challenge ourselves and others to strive for meaningful change. We asked employees to recognize role models who …

/by

Novartis announces change to the Executive Committee

  • Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021

  • Thomas Kendris appointed Chief Legal Officer ad interim

Basel, March 5, 2021 — Novartis announced today that Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down from the Executive Committee of Novartis (ECN), effective March 15, 2021.

Thomas N. Kendris, currently Global Head Litigation and US Country President …

/by

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

  • Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.
  • Novartis plans to manufacture the mRNA and bulk drug product of the CVnCoV vaccine candidate for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022. Delivery from manufacturing site in Kundl, Austria expected to start in summer 2021.
  • One of several agreements Novartis is reviewing on a global basis to help …
/by